Azimilide Dihydrochloride; Placebo; Sotalol
Проводит Forest Laboratories
Страница компанииEfficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00035451/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 658 чел. во всех странах исследования.
- Центров в реестре: 19 в 2 городах. Список — ниже на странице.
- Плановая дата окончания (06.2003) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 3
Критерии включения
- Documented (12-lead ECG) history of symptomatic atrial fibrillation occurring between 48 hours and 6 months before screening
- Require the procedure of cardioversion (electric shock to correct abnormal rhythm)
- In the investigator's opinion, is likely to maintain sinus rhythm after cardioversion.
- Be anticoagulated according to the recommendations of the Study Group on Atrial Fibrillation of the European Society of Cardiology guidelines.
Критерии невключения
- Previously unsuccessful electrical cardioversions
- Failed to respond to any Class III antiarrhythmic drugs
- Qualifying arrhythmia due to acute reversible illness, acute myocardial infarction, and/or cardiac or thoracic surgery within one month prior to randomization
Источник: ClinicalTrials.gov, NCT00035451 · запись обновлена в реестре 3 октября 2011.
Дизайн и результаты
Что измеряют — первичные конечные точки (1)
- To prolong the time to first symptomatic or asymptomatic AFIB, etc event — 6 month
Цель исследования
Atrial fibrillation (abnormal rhythm in the upper chamber of the heart) is a common supraventricular arrhythmia (a type of abnormal heart rhythm) for which antiarrhythmic therapy is often prescribed. The primary goals of therapy are to maintain sinus rhythm (normal heart rhythm) and to reduce the occurrence of episodes of atrial fibrillation.
The double-blind, placebo-controlled phase of this study is designed to evaluate the efficacy and safety of oral azimilide compared with placebo and with sotalol, an antiarrhythmic drug, in maintaining sinus rhythm in patients who require cardioversion (electric shock to correct heart rhythm) to correct atrial fibrillation. Once this phase of the study is completed, a second phase with a different study design will be conducted. The second phase is an open-label, follow-up phase to the first study. The follow-up phase will continue to evaluate the long-term safety of a daily oral dose of azimilide in patients who complete the double-blind, placebo-controlled phase of this study.
Где проходит
19 центров в 2 городах- Cardiology Department Moscow Sechenov Medical Academy
- Cardiology Department of State Medical Academy of Postgraduate Education, Myasnikov Clinical Cardiology Research Institute
- Cardiology Department, Moscow Clinical Hospital No. 59
- Department of Emergency Cardiology Russian Cardiology Research Centre
- Department of Internal Disease No. 5, Moscow State University of Medicine and Stomatology, Cardiology Department Moscow City Hospital No. 11
- Medical Centre of General Management Department of the President of the Russian Federation, Cardiology Department Moscow Clinical Hospital No. 51
- Moscow State Institute of Peace and Friendship Pharmacology Department, Moscow Clinical Hospital #64
- Moscow State University of Medicine and Stomatolog, Cardiology Department of Moscow Clinical Hospital No. 50
- President's Medical Center
- Res. Inst. of Physical and Chemical Medicine Department of Cardiology Moscow Clinical Hospital No. 29
- Russian State Medical University Clinical facility: Cardiology Department of City Clinical Hospital No. 4
- Cardiology Department Alexandrovskiy Hospital
- Cardiology Department St Petersburg Hospital No. 2
- Cardiology Department St. Petersburg State Pavlov Medical University
- Cardiology Department, St Petersburg Hospital, No. 15
- Cardiology Department, State Research Institute
- Department of Cardiology No. 3 Pokrovskiy Hospital
- Myocardial Infarction Department St Elizabeth Hospital
- Myocardial Infarction Department St Petersburg Hospital, No. 28
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00035451 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.